Azitra, Inc.

AZTR

US05479L1044

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 16:10:00 2024-06-12 EDT			5-day change	1st Jan Change
0.1514 ^USD	+0.93%		-10.10%	-83.54%

05-10	Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting	CI
05-09	Azitra, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Azitra, Inc.(NYSEAM:AZTR) added to S&P TMI Index

September 18, 2023 at 12:00 am

Latest news about Azitra, Inc.

Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting	05-10	CI
Azitra, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting	04-22	CI
Azitra, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-15	CI
Azitra Closes $5 Million Public Offering	02-16	MT
Top Midday Decliners	02-14	MT
Azitra Prices Stock Offering at $0.30 a Share	02-14	MT
Azitra Launches Common Stock Offering; Shares Drop	01-19	MT
Certain Warrants of Azitra, Inc. are subject to a Lock-Up Agreement Ending on 16-DEC-2023.	12-15	CI
Certain Options of Azitra, Inc. are subject to a Lock-Up Agreement Ending on 16-DEC-2023.	12-15	CI
Certain Common Stock of Azitra, Inc. are subject to a Lock-Up Agreement Ending on 16-DEC-2023.	12-15	CI
Earnings Flash (AZTR) AZITRA Posts Q3 Revenue $310,700	11-14	MT
Azitra, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	11-14	CI
Azitra, Inc.(NYSEAM:AZTR) added to S&P TMI Index	23-09-18	CI
Earnings Flash (AZTR) AZITRA Reports Q2 Revenue $172,000	23-08-14	MT
Azitra Adds Barbara Ryan and John Schroer to Its Board of Directors	23-07-19	CI
Azitra Names Travis Whitfill as Chief Operating Officer	23-07-11	MT
Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer	23-07-10	CI
Top Premarket Decliners	23-07-06	MT
Insider Buy: Azitra	23-06-26	MT
Insider Buy: Azitra	23-06-26	MT
Azitra Closes IPO, Raises $7.5 Million Gross Proceeds	23-06-22	MT
Azitra Shares Fall in NYSE American Debut	23-06-16	MT
Azitra Prices Initial Public Offering; Expects to Start Trading on Friday	23-06-16	MT
Azitra, Inc. has completed an IPO in the amount of $7.5 million.	23-06-15	CI

Azitra, Inc. is an early-stage clinical biopharmaceutical company. The Company is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. It has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. The Companyâs product ATR-12 is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its product ATR-04 is a genetically modified strain of S. epidermidis for treating the papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease.

Sector

Biotechnology & Medical Research

Calendar

2024-08-11 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.1514 USD

Average target price

3.5 USD

Spread / Average Target

+2,211.76%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AZITRA, INC.	-83.54%	4.36M
MODERNA, INC.	+48.54%	56.61B
IQVIA HOLDINGS INC.	-6.02%	39.62B
LONZA GROUP AG	+37.09%	39.25B
CELLTRION, INC.	-6.90%	28.28B
ICON PUBLIC LIMITED COMPANY	+12.97%	26.44B
ALNYLAM PHARMACEUTICALS, INC.	-16.91%	20.12B
UNITED THERAPEUTICS CORPORATION	+28.18%	12.51B
MEDPACE HOLDINGS, INC.	+31.71%	12.48B
BIO-TECHNE CORPORATION	+0.38%	12.2B

Other Biotechnology & Medical Research

Azitra, Inc.

Equities

AZTR

US05479L1044

Biotechnology & Medical Research

Azitra, Inc.(NYSEAM:AZTR) added to S&P TMI Index

Latest news about Azitra, Inc.

Chart Azitra, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research